The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

被引：75

作者：

Conroy, Thierry ^{[1
,2
,3
]}

Gavoille, Celine ^{[3
]}

Samalin, Emmanuelle ^{[4
]}

Ychou, Marc ^{[4
]}

Ducreux, Michel ^{[5
]}

机构：

[1] Univ Lorraine, Ctr Alexis Vautrin, EA 4360, F-54519 Vandoeuvre Les Nancy, France

[2] Univ Lorraine, Ctr Alexis Vautrin, Dept Med Oncol, F-54519 Vandoeuvre Les Nancy, France

[3] Ctr Alexis Vautrin, Dept Med Oncol, F-54519 Vandoeuvre Les Nancy, France

[4] Ctr Val Aurelle, Dept Med Oncol, F-34298 Montpellier 5, France

[5] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France

来源：

CURRENT ONCOLOGY REPORTS | 2013年 / 15卷 / 02期

关键词：

Pancreatic cancer; Chemotherapy; Oxaliplatin; Irinotecan; QUALITY-OF-LIFE; PHASE-III TRIAL; OXALIPLATIN FOLFIRINOX; MODIFIED FOLFOXIRI; GEMCITABINE; COMBINATION; IRINOTECAN; CHEMOTHERAPY; EXPERIENCE; GERCOR;

D O I：

10.1007/s11912-012-0290-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.

引用

页码：182 / 189

页数：8

共 40 条

[1]

[Anonymous], J CLIN ONCOL S

[2]

[Anonymous], J CLIN ONCOL S

[3] 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma [J].

Assaf, Elias ;

Verlinde-Carvalho, Muriel ;

Delbaldo, Catherine ;

Grenier, Julien ;

Sellam, Zineb ;

Pouessel, Damien ;

Bouaita, Linda ;

Baumgaertner, Isabelle ;

Sobhani, Iradj ;

Tayar, Claude ;

Paul, Muriel ;

Culine, Stephane .

ONCOLOGY, 2011, 80 (5-6) :301-306

[4]

Attard CL, 2012, J CLIN ONCOL S, V30

[5]

Bendell JC, 2011, J CLIN ONCOL S, V29

[6]

Breysacher G, 2010, J CLIN ONCOL S, V28

[7] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[8] Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement [J].

Callery, Mark P. ;

Chang, Kenneth J. ;

Fishman, Elliot K. ;

Talamonti, Mark S. ;

Traverso, L. William ;

Linehan, David C. .

ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) :1727-1733

[9] Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer -: A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer Study [J].

Conroy, T ;

Paillot, B ;

François, E ;

Bugat, R ;

Jacob, JH ;

Stein, U ;

Nasca, S ;

Metges, JP ;

Rixe, O ;

Michel, P ;

Magherini, E ;

Hua, A ;

Deplanque, G .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1228-1236

[10]

Conroy T, 2011, B CANC, V98, P1438

← 1 2 3 4 →